BASKING RIDGE, N.J. (February 5, 2019) – Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune disease, announced today that management will present at the following conferences in February:
2019 BIO CEO & Investor Conference
Date & Time: Tuesday, February 12, 2019 at 9:30 a.m. (EST)
Presenter: David Mazzo, Ph.D., President and Chief Executive Officer
Venue: New York Marriott Marquis in New York City
A live and archived webcast of Dr. Mazzo’s presentation will be available under the Investor Relations section of the Company’s website at www.caladrius.com.
Japan Endovascular Treatment Conference of 2019
Title: Latest treatment strategy for CLI (including information of CLBS12 trial)
Date & Time: Friday, February 22, 2019 at 12:10 p.m. (JST)
Presenter: Douglas Losordo, M.D., FACC, FAHA, Executive Vice President, Global Head of Research and Development, Chief Medical Officer
Venue: TKP Garden City Shinagawa in Tokyo, Japan
About Caladrius Biosciences
Caladrius is a late-stage therapeutics development biopharmaceutical company committed to the development of innovative products that have the potential to restore the health of people with chronic illnesses. Our leadership team collectively has decades of biopharmaceutical development experience and world-recognized scientific achievement in the fields of cardiovascular and autoimmune disease, among other areas. The Company’s goal is to build a broad portfolio of novel and versatile products that address important unmet medical needs. Our current product candidates include three developmental treatments for cardiovascular diseases based on our CD34 cell therapy platform: CLBS12, recipient of SAKIGAKE designation, in Phase 2 testing in Japan and eligible for early conditional approval for the treatment of critical limb ischemia; CLBS14-CMD, in Phase 2 testing for the treatment of coronary microvascular dysfunction and CLBS14-NORDA (formerly CLBS14-RfA) in late-stage development for no option refractory disabling angina for which it has received RMAT designation. Caladrius’ autoimmune product candidate in Phase 2 testing, CLBS03, is an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes. CLBS03 has been awarded Fast Track and Orphan designations by the FDA. For more information on the company, please visit www.caladrius.com.
Caladrius Biosciences, Inc.
Vice President, Investor Relations and Corporate Communications
# # #